Technology Sana CEO reveals details about stealthy gene therapy startup that has raised more than $700M

08:15  24 october  2020
08:15  24 october  2020 Source:   geekwire.com

The shield or the magnolia? Here are the final two options for the new Mississippi state flag

  The shield or the magnolia? Here are the final two options for the new Mississippi state flag The commission will meet again on Sept. 2 to pick a winner. The public will vote on whether to accept the final design in November.Kenosha Board Supervisor: 'This resparks the flame' of tensions nationwide

Sana Biotechnology today formally announced that it has raised more than $ 700 million in venture funding — one of the largest venture financing deals in the… “ Sana is dedicated to modulating genes in cells as well as replacing damaged cells in the body,” Sana CEO Steve Harr said in a press release.

Gene editing has been a potential therapy for many genetic , autoimmune diseases and also for immunotherapy. Country: USA | Funding: $ 700 M Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

a person sitting at a table in front of a television: Luke Timmerman interviews Sana Biotechnology CEO Steve Harr at the GeekWire Summit this week. © Provided by Geekwire Luke Timmerman interviews Sana Biotechnology CEO Steve Harr at the GeekWire Summit this week.

Sana Biotechnology CEO Steve Harr shed more light on one of most secretive, heavily funded startups in Seattle and the global biotech industry — detailing its plans to create tools that replace and repair human body cells, with the potential to treat various diseases and create new medicines.

Harr spoke with biotechnology journalist Luke Timmerman, founder of The Timmerman Report, this week at the GeekWire Summit. Sana raised more than $700 million this summer in one of the largest venture financing deals in the life sciences industry and one of the biggest rounds on record in Seattle.

Amazon vets raise $4M from Madrona, Bezos Expeditions, others for AI2 spinout WhyLabs

  Amazon vets raise $4M from Madrona, Bezos Expeditions, others for AI2 spinout WhyLabs Company leaders know they need to implement artificial intelligence and machine learning technologies within their businesses to stay ahead of the competition. But studies show that most organizations aren’t yet seeing an impact from AI investments and are increasingly wary of potential risks related to the burgeoning tech. © Provided by Geekwire The WhyLabs team. © Provided by Geekwire WhyLabs CEO Alessya Visnjic. (WhyLabs Photo) WhyLabs wants to help.

Hexavest of Montreal more than halved its investment in AT&T stock, and cut about a third from positions in Newmont and Barrick Gold in the third quarter. It also initiated a position in Wells Fargo stock.

What Roberts was about to do has been characterised by scientists and bioethicists as everything Roberts is not the first person to inject himself with an unregulated gene therapy . By the time he took the blood test, the Facebook Live video of the injection had been viewed more than 20,000 times.

Founded in 2019, the 250-person company has an ambitious goal of both repairing cells in the body (gene therapy) and also replacing damaged cells (cell therapy). It’s led by several former executives from Juno Therapeutics, another Seattle biotech company that went public in 2014 and sold to Celgene for $9 billion in 2018.

Sana has kept a relatively low profile since launching. It is competing with much larger entities that have deeper pockets and more robust logistics capabilities. But Harr said a startup such as Sana has a key differentiator.

“We have one competitive advantage: we can make faster and better decisions,” he said. “We get there because we have better people, we have greater focus, and we have better communication.”

Seattle gene therapy biotech startup Immusoft raises $4.5M

  Seattle gene therapy biotech startup Immusoft raises $4.5M Seattle-based biotech startup Immusoft raised another $4.5 million and landed a $467,000 NIH grant to help further development of its drugs that treat genetic diseases. © Provided by Geekwire Seattle gene therapy biotech startup Immusoft raises $4.5M Founded in 2009, Immusoft develops immune cell technology that uses blood cells from a patient to create therapeutic proteins targeted to treat diseases. Its lead candidate, ISP-001, treats Mucopolysaccharidosis type I, or MPS I, and has both orphan drug and rare pediatric disease designations from the FDA.

He says Meru has treated 700 patients and it currently has 20 physicians. Most patients access the service through their employers and insurers, including Aurora Public Schools in Colorado, John Muir Medical Group and the Palo Alto Medical Foundation. But with the end of the

Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation The treatment approach can be in more than one mode, including: Replacing a disease-causing mutated gene with a healthy copy of the gene .

Read on for key takeaways from the conversation.

How Sana started: Harr and his former colleagues at Juno learned a lot about engineering cells and manipulating genes during their startup journey. Juno was among a handful of U.S. companies making cutting-edge cancer immunotherapy treatments.

But they also knew there was more opportunity in a nascent industry of gene and cell therapy.

“We wanted to build the transformative or winning company of this next era, of the next 20 years,” Harr said. “To do that, we had to break the model of what biotech is, which is typically taking an idea and figuring out where to apply it best.”

Sana instead is trying to build the platform that can engineer cells and fix them, much like building a computer.

“There are a whole host of component parts that go into it,” Harr said. “We have to aggregate the right technologies.”

Harr said too many biotech companies sell solutions in search of problems. He likened it to someone showing up with a tiny screwdriver and looking for a loose screw to fix. Harr sees Sana more as a toolbox that can help build the right medicine for the right patient.

Amy Schumer Shares Sweet Video of the 'Nice Moment' Son Gene, 16 Months, Says the Word 'Mom'

  Amy Schumer Shares Sweet Video of the 'Nice Moment' Son Gene, 16 Months, Says the Word 'Mom' "The world is burning, but this was a nice moment," the proud mom wrote on Instagram "The world is burning, but this was a nice moment," Schumer captioned the post on Instagram. "Please make a voting plan and make sure everyone in your phone has a voting plan supermajority.com can help.

Intel (INTC) CEO Bob Swan now runs one of the world’s biggest semiconductor companies, but he once led a The company filed to go public last month.(Add details on arrest in third paragraph)For German prosecutors have been more aggressive than their Danish counterparts and have already

This is more than 7x the average found among S&P listed dividend payers.Liam Burke, of B. Riley FBR, counts himself as a fan. Second Quarter EPS was 29 cents; that was lower than Q1, but higher than 4Q19.Hess has turned its steady earnings to shareholders’ advantage, with a dividend that has

Sana is targeting various disease areas, including cancer, diabetes, genetic disorders, and more. “They are relatively diverse, but there are some really fundamental underlying platform and strategy principles that drive each of those,” Harr said.

a couple of people posing for the camera: Luke Timmerman (left) interviews Sana Biotechnology CEO Steve Harr. © Provided by Geekwire Luke Timmerman (left) interviews Sana Biotechnology CEO Steve Harr.

Sana’s secret sauce: One key focus for the company is reimagining the delivery system for these therapies — how to get DNA, RNA, proteins, etc. into a cell. “Ultimately at the core, what we’re trying to do is really improve delivery, and really figure out how to hide cells from the immune system,” Harr said.

Hiding re-engineered or replaced cells from one’s immune system is important to prevent the possibility of the body rejecting the new cells.

Harr also talked about delivering therapy via injection, with the body becoming the “bioreactor.” It’s similar to technology built by Moderna and others. “You deliver the tools to enable your body to make its own medicine,” Harr said.

Manufacturing: Sana is also aiming to innovate how gene and cell therapies are produced and distributed at scale. They are typically expensive — Timmerman said CAR T-cell immunotherapies for cancer ran in the $300,000-to-$400,000 range per patient. Figuring out manufacturing costs at scale and making it less than current alternative methods of care for patients will be key to the strength of Sana’s business. Harr added that “you have to do it in a way that’s constructive for the system.”

New Zealand prime minister's party promises to ban conversion therapy

  New Zealand prime minister's party promises to ban conversion therapy New Zealand Prime Minister Jacinda Ardern's ruling party plans to ban conversion therapy if reelected, an official said this week."Conversion therapy has been linked to severe adverse mental health issues, including depression, anxiety and suicidal ideation - that's why it will be banned under a reelected Labour Government," Labour Party leader Tāmati Coffey told Reuters. "It is a practice that causes harm and is out of place in the kind, inclusive and modern country we are," he continued.

PNW startups raised more than B in Q3 — here’s why investors are still making bets amid Secretive Seattle-area blockchain startup Core Scientific is raising a big 0 million investment Whitcomb, a former CTO and co-founder at Myspace, declined to provide details about how Core

The lab started working through a pipeline of more than 60 different gene therapies , which it is testing on old mice, alone and in combinations. The Harvard group now plans to publish a scientific report on a technique that extends rodents’ lives by modifying two genes to act on four major diseases of aging

Headcount: Sana employs 250 people spread across offices in Seattle, the Bay Area, and Cambridge, Mass. Having three outposts helps the company attract the best talent, Harr said. One advantage to raising so much capital is being able to hire the best folks. Last month Sana added top scientists Ed Rebar and Terry Fry to the executive team.

“If you really hire one of the true world leaders in something, it is pretty amazing how quickly teams form around them,” Harr noted.

Money matters: Having more than $700 million in the bank helps Sana in various other ways. Harr said a lot of biotech companies often run what amount to experiments to justify raising more capital. “We have the privilege of running experiments to find truth as fast as you want to,” he said. “And then we want to have the balance sheet, technologies, and people to be able to grapple with whatever the truth is.”

Timeline: Harr said the company is on track with its original strategy but does not plan on selling medicine in the next two years. It will progress with multiple medicines in parallel, not one at a time, Harr said.

Leadership advice: During the pandemic and remote work, Harr said he’s started to reach out to four-to-six people at Sana each week that he wouldn’t normally talk with. He holds half-hour meetings to chat about what they are working on, and what leadership could do to make their life or job better. “I found that to be just such an invigorating way to learn what’s going on,” he said.

[The full interview with Harr, and other GeekWire Summit sessions, are available on-demand exclusively to attendees of the virtual event. Learn more and register here.]

Syria: the mufti of Damascus killed in an attack .
© AFP Location map of the city of Qoudsaya The mufti of Damascus province, Adnane al-Afyouni, was killed Thursday in a bomb explosion placed in his vehicle near the Syrian capital, reported the official Sana agency denouncing a "terrorist" attack.

usr: 2
This is interesting!